The COVID-19 outbreak in Sichuan, China: Epidemiology and impact of interventions.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
24
07
2020
accepted:
26
10
2020
revised:
08
01
2021
pubmed:
29
12
2020
medline:
20
1
2021
entrez:
28
12
2020
Statut:
epublish
Résumé
In January 2020, a COVID-19 outbreak was detected in Sichuan Province of China. Six weeks later, the outbreak was successfully contained. The aim of this work is to characterize the epidemiology of the Sichuan outbreak and estimate the impact of interventions in limiting SARS-CoV-2 transmission. We analyzed patient records for all laboratory-confirmed cases reported in the province for the period of January 21 to March 16, 2020. To estimate the basic and daily reproduction numbers, we used a Bayesian framework. In addition, we estimated the number of cases averted by the implemented control strategies. The outbreak resulted in 539 confirmed cases, lasted less than two months, and no further local transmission was detected after February 27. The median age of local cases was 8 years older than that of imported cases. We estimated R0 at 2.4 (95% CI: 1.6-3.7). The epidemic was self-sustained for about 3 weeks before going below the epidemic threshold 3 days after the declaration of a public health emergency by Sichuan authorities. Our findings indicate that, were the control measures be adopted four weeks later, the epidemic could have lasted 49 days longer (95% CI: 31-68 days), causing 9,216 more cases (95% CI: 1,317-25,545).
Identifiants
pubmed: 33370263
doi: 10.1371/journal.pcbi.1008467
pii: PCOMPBIOL-D-20-01325
pmc: PMC7794025
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008467Déclaration de conflit d'intérêts
H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. A.V. reports grants from Metabiota inc., outside the submitted work. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Science. 2020 May 15;368(6492):742-746
pubmed: 32269067
Lancet Infect Dis. 2020 Nov;20(11):1247-1254
pubmed: 32621869
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
Lancet Infect Dis. 2020 May;20(5):553-558
pubmed: 32171059
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11220-11222
pubmed: 32366658
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Science. 2020 May 8;368(6491):638-642
pubmed: 32234804
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12680-12685
pubmed: 30463945
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437